List of Pizensy drug patents

Pizensy is owned by Braintree Labs.

Pizensy contains Lactitol.

Pizensy has a total of 1 drug patent out of which 0 drug patents have expired.

Pizensy was authorised for market use on 12 February, 2020.

Pizensy is available in for solution;oral dosage forms.

Pizensy can be used as method of treating chronic idiopathic constipation in adult patients..

Drug patent challenges can be filed against Pizensy from February, 2024.

The generics of Pizensy are possible to be released after 12 May, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in